Format

Send to

Choose Destination
J Med Chem. 2015 Oct 22;58(20):7928-30. doi: 10.1021/acs.jmedchem.5b01394. Epub 2015 Sep 16.

Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists.

Author information

1
Evotec (UK) Ltd. , 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom.
2
Department of Biochemistry, University of Oxford , South Parks Road, Oxford OX1 3QU, United Kingdom.

Abstract

In this issue, Nagase and colleagues report the discovery of the first selective nonpeptidic orexin 2 receptor (OX2R) agonists. The discovery of these OX2R selective agonists opens up new avenues for therapies related to the activation of the orexin system, especially with respect to the treatment of sleep disorders such as narcolepsy.

PMID:
26375584
DOI:
10.1021/acs.jmedchem.5b01394
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center